RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src

Overexpression of EGFR is commonly seen in gastric cancer (GC). However, patients with GC show resistance to anti-EGFR treatments. RAS mutations are rare in GC and cannot explain de novo resistance to EGFR treatments. Therefore, it is particularly important to explore the mechanisms of resistance to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Onco Targets Ther
Autores principales: Zhang, Xiaomeng, Song, Yongxi, Song, Na, Zhang, Ye, Zhang, Lingyun, Wang, Yan, Wang, Zhenning, Qu, Xiujuan, Liu, Yunpeng
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5229171/
https://ncbi.nlm.nih.gov/pubmed/28123301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S110918
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares